- Trial Phase
- Preclinical / Early-stage (no registered clinical trials found)
- Time to Market
- Unknown — drug appears to be preclinical or very early-stage with no registered clinical trials; likely 5+ years from potential approval, if ever.
- Why 2/10
- CY200 has no scheduled hard catalyst (PDUFA, pivotal readout, or advisory committee) within the next ~12 months. Its most recent milestone — FDA Orphan Drug Designation (Aug 13, 2026) — is already past. The drug appears pre/early-clinical with no registered trials. As a small part of a struggling micro-cap pipeline whose lead asset is PF614-MPAR, CY200 alone cannot drive a meaningful share-price move. Impact score is low.
CY200 is early-stage and not the company's lead asset (PF614-MPAR with Breakthrough Therapy designation is the closer-to-market program). For ENSC, the more immediate catalysts are the Nasdaq listing compliance deadline (Feb 2027), the potential preferred share conversion/dilution overhang, and any clinical updates on lead programs. CY200 alone is unlikely to move the stock significantly in the next 12 months without a funded clinical trial start.
Price Chart
Executive Summary
CY200 is an early-stage, abuse-deterrent opioid candidate from Ensysce Biosciences (ENSC, ~$0.47/share, ~$10M market cap) targeting Complex Regional Pain Syndrome Type 1 (CRPS-1). The drug received FDA Orphan Drug Designation in August 2026, but appears to be pre-clinical or very early-stage with no registered clinical trials. Ensysce is a micro-cap company facing severe financial distress: Nasdaq delisting risk (bid price below $1.00), going concern audit qualifications, and a recent S-3 filing registering ~434M shares (22x current float) for potential resale. While director insider buying and a Strong Buy analyst consensus (mean target $5.125) provide some bullish signals, CY200 alone is unlikely to drive near-term share-price movement — the company's lead asset is PF614-MPAR (which has Breakthrough Therapy designation), and CY200 remains a preclinical pipeline program with no imminent catalysts.
How It Works
CY200 is believed to be an abuse-deterrent opioid formulation from Ensysce's TAAP (Trypsin-Activated Abuse Protection) platform. The TAAP technology is designed so that the opioid drug is only activated when it reaches the small intestine, where the digestive enzyme trypsin breaks down a protective coating. This prevents the drug from working if crushed (for snorting) or dissolved (for injection), reducing abuse potential while still providing oral pain relief. CY200 is being developed specifically for Complex Regional Pain Syndrome Type 1, a rare chronic pain condition that typically develops after an injury or surgery.
Trial Status
No ClinicalTrials.gov registered trials identified for CY200. The drug has received FDA Orphan Drug Designation for CRPS Type 1 (Aug 2026), but appears not yet to have entered human clinical testing. The company has not publicly disclosed specific trial timelines for CY200 as of this report.
The Two-Sided Case
Upcoming Catalysts
- Any announcement of an IND filing or clinical trial initiation for CY200 would be a positive signal but is not currently scheduled.
- The more material near-term catalysts for ENSC are: Nasdaq bid-price compliance deadline (Feb 22, 2027), stockholder vote on preferred stock conversion, and clinical updates on lead asset PF614-MPAR (which has Breakthrough Therapy designation).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ensysce Biosciences, Inc. S-3 ENSC ·Originating report